Ryan J. Watts Sells 18,334 Shares of Denali Therapeutics Inc (DNLI) Stock

Denali Therapeutics Inc (NASDAQ:DNLI) insider Ryan J. Watts sold 18,334 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $18.09, for a total transaction of $331,662.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

NASDAQ DNLI traded up $1.29 during trading on Thursday, reaching $18.78. 688,500 shares of the stock traded hands, compared to its average volume of 378,975. The stock has a market cap of $1.58 billion and a P/E ratio of -3.19. Denali Therapeutics Inc has a fifty-two week low of $12.32 and a fifty-two week high of $25.79.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.13). The company had revenue of $1.20 million for the quarter, compared to analysts’ expectations of $3.00 million. On average, analysts forecast that Denali Therapeutics Inc will post -0.75 EPS for the current year.

A number of equities research analysts recently weighed in on DNLI shares. Zacks Investment Research downgraded shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 14th. Cantor Fitzgerald started coverage on shares of Denali Therapeutics in a research note on Wednesday. They set an “overweight” rating and a $25.00 price target for the company. Finally, Janney Montgomery Scott started coverage on shares of Denali Therapeutics in a research note on Monday. They set a “buy” rating and a $26.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $24.00.

A number of hedge funds and other institutional investors have recently modified their holdings of DNLI. BlackRock Inc. grew its holdings in Denali Therapeutics by 194.9% during the third quarter. BlackRock Inc. now owns 3,307,050 shares of the company’s stock valued at $71,896,000 after purchasing an additional 2,185,692 shares during the period. Jasper Ridge Partners L.P. acquired a new position in Denali Therapeutics during the second quarter valued at approximately $4,289,000. Millennium Management LLC acquired a new position in Denali Therapeutics during the second quarter valued at approximately $2,623,000. Northern Trust Corp acquired a new position in Denali Therapeutics during the first quarter valued at approximately $3,309,000. Finally, Baillie Gifford & Co. grew its holdings in Denali Therapeutics by 2.9% during the second quarter. Baillie Gifford & Co. now owns 5,344,633 shares of the company’s stock valued at $81,506,000 after purchasing an additional 151,787 shares during the period. Hedge funds and other institutional investors own 65.10% of the company’s stock.

WARNING: “Ryan J. Watts Sells 18,334 Shares of Denali Therapeutics Inc (DNLI) Stock” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.wkrb13.com/2018/11/16/ryan-j-watts-sells-18334-shares-of-denali-therapeutics-inc-dnli-stock.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Featured Story: How Important is Technical Analysis of Stocks

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply